Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062707 | 0.83 | ABCB1 (0.77) | ABCB1 | |
| SCHEMBL5058394 | 0.83 | ABCB1 (0.64) | ABCB1 | |
| SCHEMBL5057245 | 0.82 | ABCB1 (0.68) | ABCB1 | |
| SCHEMBL9102771 | 0.81 | ABCB1 (0.64) | ABCB1 | |
| SCHEMBL8998725 | 0.81 | ABCB1 (0.70) | ABCB1 | |
| SCHEMBL8998827 | 0.81 | ABCB1 (0.67) | ABCB1 | |
| SCHEMBL8383526 | 0.81 | ABCB1 (0.80) | ABCB1 | |
| SCHEMBL5056990 | 0.81 | ABCB1 (0.76) | ABCB1 | |
| SCHEMBL7701546 | 0.80 | ABCB1 (0.71) | ABCB1 | |
| SCHEMBL8998705 | 0.80 | ABCB1 (0.78) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040389-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | Intrexon Coporation (US) | 2013-02-14 | — | — | US | claimed |
| EP-2463269-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-13 | — | — | EP | claimed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | claimed |
| EP-1601642-A4 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2007-04-11 | — | — | EP | claimed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | claimed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2460786-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2463269-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2460786-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885ALDH1A1 3129/4885RAB9A 4777/4885 |
| US-20130040389-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885ALDH1A1 3129/4885RAB9A 4777/4885 |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885ALDH1A1 3129/4885RAB9A 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.